Here, we show that treatment of PCa cells with enzalutamide diminishes cytoplasmic AR in 22Rv1 cells, suggesting that enzalutamide impairs agonist binding whereas ISA-2011B eliminates the nuclear AR expression, through PIP5K1α and CDK1. The gene discussed is AR; the disease is posterior cortical atrophy.